Clinical trial NCT02433301 - References

Gastroesophageal Junction Cancer — PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy

Citation(s)

•   Basu S, Alavi A
  Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008 Oct;49(10):17N-21N, 37N. Review.
•   Gambhir SS
  Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002 Sep;2(9):683-93. Review.
•   Jadvar H, Colletti PM
  Competitive advantage of PET/MRI. Eur J Radiol. 2014 Jan;83(1):84-94. doi: 10.1016/j.ejrad.2013.05.028. Epub 2013 Jun 18. Review.
•   Larsen AC, Holländer C, Duval L, Schønnemann K, Achiam M, Pfeiffer P, Yilmaz MK, Thorlacius-Ussing O, Bæksgaard L, Ladekarl M
  A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors. Ann Surg Oncol. 2015 May;22(5):1540-7. doi: 10.1245/s10434-014-4127-2. Epub 2014 Oct 28.
•   Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL
  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009 Feb;11(2):102-25.
•   Rakheja R, Chandarana H, DeMello L, Jackson K, Geppert C, Faul D, Glielmi C, Friedman KP
  Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. AJR Am J Roentgenol. 2013 Nov;201(5):1115-9. doi: 10.2214/AJR.13.11304.
•   Thoeny HC, Ross BD
  Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging. 2010 Jul;32(1):2-16. doi: 10.1002/jmri.22167. Review.
•   Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C
  Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction. J Gastrointestin Liver Dis. 2013 Mar;22(1):45-52.
•   Zhu W, Xing L, Yue J, Sun X, Sun X, Zhao H, Yu J
  Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol. 2012 Sep;85(1017):e694-701. doi: 10.1259/bjr/29946900. Epub 2012 Feb 14. Review.

PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer

Details for clinical trial NCT02433301